Zonisamide + Placebo

Phase 3Terminated

0 views this week 0 watching💤 Quiet

Interest: 32/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Epilepsy

Conditions

Epilepsy

Trial Timeline

Jun 1, 2008 → —

NCT ID

NCT00693017

About Zonisamide + Placebo

Zonisamide + Placebo is a phase 3 stage product being developed by Eisai for Epilepsy. The current trial status is terminated. This product is registered under clinical trial identifier NCT00693017. Target conditions include Epilepsy.

What happened to similar drugs?

20 of 20 similar drugs in Epilepsy were approved

Approved (20) Terminated (6) Active (0)

✅ZonegranEisaiApproved

✅Perampanel + PlaceboEisaiApproved

✅perampanelEisaiApproved

✅Perampanel Oral TabletEisaiApproved

✅PerampanelEisaiApproved

✅zonisamide low dose group + zonisamide high dose groupEisaiApproved

✅Zonisamide at targeted daily doses of 100-500 mg/day + Placebo administered to match targeted daily doses of 100-500 mg/dayEisaiApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (5)

NCT ID	Phase	Status	Start	Completion	Indication
NCT01765608	Phase 2	Completed	Mar 1, 2010	Jun 1, 2013	Sleep Apnea
NCT00566254	Phase 3	Completed	Dec 1, 2008	Mar 1, 2011	Epilepsy; Paediatric Partial Onset Seizures
NCT00692003	Phase 3	Terminated	Aug 1, 2008	Jan 9, 2009	Epilepsy
NCT00693017	Phase 3	Terminated	Jun 1, 2008	—	Epilepsy
NCT00327717	Phase 3	Completed	Sep 1, 2006	May 1, 2008	Partial Seizures

Competing Products

20 competing products in Epilepsy

See all competitors

Product	Company	Stage	Hype Score
perampanel	Eisai	Phase 2	35
Lacosamide	UCB	Phase 3	40
Zonegran	Eisai	Approved	35
perampanel + perampanel	Eisai	Phase 1	29
Perampanel + Placebo	Eisai	Approved	35
perampanel	Eisai	Approved	35
E2007 + Placebo	Eisai	Phase 2	35
Placebo + Rufinamide	Eisai	Phase 3	40
E2007 (perampanel) + Placebo	Eisai	Phase 2	35
Perampanel Oral Tablet	Eisai	Approved	43
perampanel	Eisai	Phase 3	40
Perampanel	Eisai	Pre-clinical	26
Zonisamide + Carbamazepine	Eisai	Phase 3	40
Perampanel	Eisai	Approved	43
Perampanel and Microgynon-30 + Perampanel and Microgynon-30	Eisai	Phase 1	29
Perampanel	Eisai	Phase 2	35
Zonisamide + Placebo	Eisai	Phase 3	40
zonisamide low dose group + zonisamide high dose group	Eisai	Approved	43
E2007 + E2007 + Placebo	Eisai	Phase 2	35
Zonisamide at targeted daily doses of 100-500 mg/day + Placebo administered to match targeted daily doses of 100-500 mg/day	Eisai	Approved	35